Advertisement

Topics

FDAnews Announces — Implementing Elemental Impurities Testing: ICH Q3D, USP and Requirements Webinar, Aug. 31, 2017

16:30 EDT 23 Aug 2017 | PR Web

Branded and generic drug and biologics makers, need to brace themselves: Next Jan. 1, every last one of their approved products will be subject to tough new standards known as ICH Q3D, USP [232] and [233].

Falls Church, VA (PRWEB) August 23, 2017

Implementing Elemental Impurities Testing:
ICH Q3D, USP [232] and [233] Requirements
**An FDAnews Webinar**
Aug. 31, 2017 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/impurities

Branded and generic drug and biologics makers, need to brace themselves: Next Jan. 1, every last one of their approved products will be subject to tough new standards known as ICH Q3D, USP [232] and [233].

ICH Q3D is the elemental impurities guideline that now affects new drugs only. Think of it as the USP standards on steroids. But with less than a half-year to comply, some manufacturers have barely started thinking about how it will affect already approved products.

FDAnews is stepping into the breach, with a must-attend webinar featuring an expert from EAG Labs to show the way. For 15+ years, Dr. Wayland Rushing has led CMC development programs for a wide array of biopharmaceutical clients including parenterals, inhalation drugs and other pharmaceuticals with complex delivery systems.

Starting with a recap of the history of elemental-impurity testing, attendees will move on to cover:

  •     Comparison of ICH Q3D vs. USP [232] and [233]
  •     Risk assessment and gathering information from suppliers
  •     Analytical strategies and techniques
  •     Challenges associated with testing
  •     Case studies of testing implementation
  •     And much more!

Drug and biologics makers, API suppliers and excipient manufacturers all will benefit from this presentation. Dr. Rushing boasts expertise in chemistry, manufacturing and controls program design, analytical development and regulatory submissions.

The FDA will broaden enforcement of ICH Q3D in no time. Now is the time to get ready. Sign up today.

Meet the Presenter:
Dr. Wayland Rushing is Director of Scientific Affairs, EAG Labs. For 15+ years he has led CMC development programs for a wide array of biopharmaceutical clients including parenterals, inhalation drugs and other pharmaceuticals with complex delivery systems. He boasts expertise in chemistry, manufacturing and controls program design, analytical development and regulatory submissions.

Who Will Benefit:

  •     Manufacturing Directors
  •     Materials Sourcing Professionals
  •     Supplier Management Professionals
  •     Testing and In-bound Materials Professionals
  •     Quality Assurance/Quality Control
  •     Regulatory Affairs

Webinar Details:
Implementing Elemental Impurities Testing:
ICH Q3D, USP [232] and [233] Requirements
**An FDAnews Webinar**
Aug. 31, 2017 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/impurities    

Tuition:
$287 per site

Easy Ways to Register:
Online:     http://www.fdanews.com/impurities                                                                                        
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/08/prweb14628098.htm

NEXT ARTICLE

More From BioPortfolio on "FDAnews Announces — Implementing Elemental Impurities Testing: ICH Q3D, USP and Requirements Webinar, Aug. 31, 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...